Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes

Fig. 6

The effect of immunotherapy on NFE2L2 patients with NSCLC in the WXPH cohort. Comparison of PD-L1 TPS (A) and TMB (B) between NFE2L2 MU and NFE2L2 WT NSCLC groups in the WXPH cohort, TPS: tumor proportion score. (C) Immunohistochemistry showing PD-L1 expression. (D) Mediastinal and lung computed CT imaging of patients before and after immunotherapy. The region of the lesion was depicted by the red arrow. (E) Fig. 6E illustrates the treatments procedure.

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us